Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

byBenzinga Newsdesk

July 21, 2022

1 minute read

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

SVB Leerink Initiates Coverage On Vaxcyte with Outperform Rating, Announces Price Target of $60

By Benzinga Newsdesk

December 16, 7:05 AM

SVB Leerink analyst David Risinger initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Outperform rating and announces Price Target of $60.

PCVX

Investor Fear Eases Slightly; US Manufacturing PMI Tops Estimates

By Lisa Levin

October 3, 2:58 AM

The CNN Money Fear and Greed index showed some easing in the fear level, but remained in the "Fear" zone on Monday. U.S. stocks closed mixed on Monday, after the U.S. Congress narrowly averted a government shutdown.

CALM

Meta Weighs Political Ad Ban In Wake Of Tougher EU Regulations

By Anusuya Lahiri

March 30, 7:45 AM

Meta Platforms, Inc (NASDAQ: META) is weighing a company-wide ban on political advertising in Europe.

GOOG

Analyst Ratings

A Closer Look at 5 Analyst Recommendations For LCI Indus

By Benzinga Insights

February 6, 3:00 PM

In the last three months, 5 analysts have published ratings on LCI Indus (NYSE:LCII), offering a diverse range…

LCII

Chardan Capital Downgrades Vascular Biogenics to Neutral

Related Posts

SVB Leerink Initiates Coverage On Vaxcyte with Outperform Rating, Announces Price Target of $60

Investor Fear Eases Slightly; US Manufacturing PMI Tops Estimates

Meta Weighs Political Ad Ban In Wake Of Tougher EU Regulations

A Closer Look at 5 Analyst Recommendations For LCI Indus